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 2 
Abstract 23 
Celecoxib, a nonsteroidal anti-inflammatory drug is frequently used to treat arthritis in 24 
humans with minimal gastrointestinal side effect compared to traditional NSAIDs. The 25 
primary aim of this study is to determine the pharmacokinetic profile of celecoxib – a 26 
selective cyclooxygenase-2 (COX-2) inhibitor in horses. Six horses were administered a 27 
single oral dose of celecoxib at 2 mg/kg (body weight).  After oral dosing, the drug reached a 28 
maximum concentration (mean ± SD) in blood of 1088 ± 324 ng/mL in 4.58 h. The 29 
elimination half-life was 13.60 ± 3.18 h and the area under the curve was 24142 ± 1096 30 
ng.mL/h. The metabolism of celecoxib in horses was via a single oxidative pathway in which 31 
the methyl group of celecoxib is oxidised to a hydroxymethyl metabolite and is further 32 
oxidised to form a carboxylic acid metabolite. Celecoxib is eliminated mainly through faeces 33 
as unchanged drug and as metabolites in urine. Therefore, instructions for a detection time 34 
following therapeutic dosing of celecoxib can be set by the racing practitioner and 35 
veterinarians to control illegal use in horse racing based on the results of this study. 36 
  37 
 38 
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 Introduction 40 
Celecoxib (4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] 41 
benzenesulfonamide is the first COX-2 inhibitor to be developed as an analgesic with less 42 
toxicity on the gastrointestinal tract (Noble et al., 2000). Despite celecoxib has been clinically 43 
proven to be effective as a therapy for many species of animals (Zhang et al., 2000; Paulson et 44 
al., 2001; Störmer et al., 2003; Ma et al., 2015) there is limited data reported in horses 45 
although being banned as doping agent by horse racing authorities (The International 46 
Federation for Equestrian Sports, n.d.). A GC/MS method using TMS derivatization and an 47 
LC/MS study have been reported to characterize the metabolites of celecoxib in horse urine 48 
(Dirikolu et al., 2001; De Kock et al., 2005). However, the urine samples were collected for a 49 
short duration and a clear determination of detection time could not be established in their 50 
reports. Further, no detailed study to show data for the drug pharmacokinetics and detection 51 
time in horses is available. As such, this study was designated to characterise the plasma 52 
pharmacokinetics, metabolism pathways and elimination route of celecoxib given orally to 53 
horses, which assess the clinical and animal welfare implications and derive regulatory advice 54 
for horse racing industry. 55 
 56 
Materials and methods 57 
Animals 58 
Six adult horses (males, male castrates and females) aged 12 to 18 years and weighing 59 
approximately 480 kg were used in the study. All animals were tagged, dewormed and housed 60 
in air-conditioned stable barns. The horses were given regular walking exercise for 30 61 
minutes twice a day. Regular physical examination was performed on each horse by the local 62 
hospital veterinarian working adjacent to this facility. The animals were fed twice a day with 63 
hay, alfalfa and grains. They had free access to water. None of the horses had any disease 64 
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history in their stable records and they were not treated with NSAIDs or other anti-65 
inflammatory drugs for at least 30 days prior to this administration study. The animals were 66 
fasted overnight prior to treatment and food was supplied after 2 hours of the first blood 67 
sample collected after drug administration. The study was approved by the Animal Ethics 68 
Committee of the Central Veterinary Research Laboratory in Dubai, U.A.E. 69 
 70 
Experimental chemicals 71 
Celecoxib and zaleplon were kind donations by Ipca Laboratories Limited, Indore, 72 
India, both having an assay purity of ≈ 99.8%. β-glucuronidase from Helix pomatia (type 73 
HP2)  and NADPH were purchased from Sigma Chemical Co. Ltd.. Hydroxymethyl 74 
celecoxib and celecoxib carboxylic acid were obtained from Alsachim (France). All organic 75 
solvents were either HPLC grade or LC/MS grade and purchased from Fisher Scientific. 76 
Horse liver microsomes were bought from Xeno Tech U.S.A for in vitro studies. 77 
 78 
Treatment and sample collection 79 
The study involved administration of a single oral solution dose of celecoxib at 2 80 
mg/kg body weight (bwt) to six horses using a naso-gastric tube. The administration was done 81 
in the presence of a clinical veterinary doctor. The drug was mixed with 250 mL of drinking 82 
water and poured into the tube using a funnel. The funnel was rinsed with another 100 mL of 83 
drinking water to ensure complete delivery of the drug into the horse stomach. Prior to drug 84 
administration an 18-guage catheter was placed either into the right or left jugular vein for the 85 
collection of blood samples. Blood samples were collected into heparinised tubes at 0, 5, 10, 86 
15, 30, 45 minutes and at 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168 and 192 hours post 87 
medication. The samples were immediately centrifuged, plasma separated and kept frozen at - 88 
20°C until use for drug analysis. A custom made diaper was tied to the animal for the 89 
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collection of urine and faeces.  Urine and faeces samples were collected whenever the animal 90 
disposed for seven days after administration and were pooled into morning and evening urine 91 
and faeces composites and stored at - 20°C until used for drug analysis. 92 
 93 
Plasma sample analysis 94 
Plasma samples were analysed by use of liquid chromatography- mass spectrometry 95 
(LC/MS). A previously validated solid phase extraction (SPE) method was carried out using 96 
automated extraction modules (RapidTrace, Biotage) and Waters SepPak C18 cartridge was 97 
used for the determination of celecoxib. Briefly, the C18 cartridge was sequentially 98 
conditioned with 3 mL of methanol and 0.1 M KH2PO4 (pH 6.0). A volume of 1 mL plasma 99 
was allowed to pass through the column. Then the column was rinsed sequentially with 1 mL 100 
0.1 M KH2PO4 : methanol (90:10) and 1 mL of 1.0 M acetic acid. Following drying for 2 101 
minutes, the drug and its metabolites were eluted with 4 mL dichloromethane. The organic 102 
solvent was dried under a gentle flow of nitrogen on a TurboVap (Biotage) at 40 °C. The 103 
residue was reconstituted in 50 µL of mobile phase. In addition to administration samples, 104 
quality control samples with the drug spiked at different concentrations (1, 10, 100, 500 and 105 
1000 ng/mL) were also assayed with each set.  106 
A stock standard was prepared by dissolving 1 mg of celecoxib in 100 mL of acetonitrile. The 107 
stock standard was further diluted by serial dilution to prepare standard solutions of 1, 100 108 
and 500 ng/mL. Similarly 1 mg of zaleplon was dissolved in 100 mL of methanol. This was 109 
further diluted to 1 µg/mL and used as internal standard. Calibration standards ranged from 1 110 
to 1000 ng/mL were prepared by adding appropriate volumes of the standard drug solutions to 111 
drug free plasma. Zaleplon was used as the internal standard. A volume of 200 µL (1 µg/mL) 112 
of the internal standard was added to the calibration and test sample and extracted as 113 
mentioned above. 114 
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The LC/MS system consisted of a Surveyor LC pump and auto sampler (Thermo Finnigan) 115 
connected to a TSQ Access (Thermo Finnigan) mass spectrometer. Chromatographic 116 
separation was performed using a Thermo Hypersil C18 column (100 x 2.1 mm ID., 5 µm 117 
particle size) using a mobile phase consisting of acetonitrile and 1% formic acid in water, run 118 
in a gradient mode. The mass spectrometer was operated in the negative ion mode performing 119 
product ion scans (m/z 380 → 316), (m/z 396 → 302) and (m/z 410 → 366) for celecoxib, 120 
hydroxymethyl celecoxib and celecoxib carboxylic acid, respectively. Zaleplon was scanned 121 
in the positive ion mode for the transition (m/z 306 → 264). 122 
The present study was able to examine the pharmacokinetics and characterize the metabolic 123 
disposition of celecoxib after a single oral dose to horses, applying the proposed highly 124 
selective and sensitive LC/MS with a limit of quantitation (LOQ) of 1 ng/mL and a limit of 125 
detection (LOD) of 500 pg/mL. No interfering peaks for celecoxib were observed in the 126 
chromatograms of blank plasma from the horses used in the study. The intra-day and inter-day 127 
assay precision and accuracy for low, medium and high (10, 100, 200 ng/mL) concentration 128 
of celecoxib in horse plasma showed a coefficient of variation percentage (CV%) ranging 129 
from 5.6 to 9.8 and 4.9 to 8.0, respectively. 130 
 131 
 132 
Pharmacokinetic analysis 133 
Pharmacokinetic parameters were determined for each animal individually utilizing 134 
application of the trapezoidal rule for measurements of plasma drug concentration versus time 135 
curve to achieve the non-compartmental methodology (Gibaldi & Perrier, 1982; Martinez, 136 
1998; Gabrielsson & Weiner, 2012) using a computerized pharmacokinetic and drug 137 
disposition program (Kinetica Version 5.1 SP1, Thermo). For each parameter, the mean and 138 
standard deviation (SD) were obtained from the calculation results of six animals (n = 6). 139 
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In order to estimate the celecoxib dose for horses from an efficacious dose in human, the 140 
following equation was applied (Toutain & Bousquet-Mélou, 2004): 141 
𝐷𝑜𝑠𝑒ℎ𝑜𝑟𝑠𝑒 =
𝐷𝑜𝑠𝑒ℎ𝑢𝑚𝑎𝑛×𝐶𝐿ℎ𝑜𝑟𝑠𝑒
𝐶𝐿ℎ𝑢𝑚𝑎𝑛
   (1) 142 
In addition, determinations of an effective plasma concentration (EPC), irrelevant plasma 143 
concentration (IPC), safety factor (SF) and detection time (DT) were based on the following 144 
equations (Toutain & Lassourd, 2002): 145 
𝐸𝑃𝐶 =  
𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑜𝑠𝑒 (𝑝𝑒𝑟 𝑑𝑜𝑠𝑖𝑛𝑔 𝑖𝑛𝑡𝑒𝑟𝑣𝑎𝑙)
𝑝𝑙𝑎𝑠𝑚𝑎 𝑐𝑙𝑒𝑎𝑟𝑎𝑛𝑐𝑒 (𝑝𝑒𝑟 𝑑𝑜𝑠𝑖𝑛𝑔 𝑖𝑛𝑡𝑒𝑟𝑣𝑎𝑙)
  (2) 146 
𝐼𝑃𝐶 =  
𝐸𝑃𝐶
𝑆𝐹
      (3) 147 
𝐼𝑃𝐶 =  𝐶𝑚𝑎𝑥  ×  𝑒
(−𝛽 ×𝐷𝑇)    (4) 148 
 149 
Determination of metabolites 150 
Urine samples were pooled as ‘0’ hour (control), 1-12, 12-24 hours and so on up to 151 
192 hours after administration. An aliquot of 10 mL of each urine sample was adjusted to pH 152 
5.2 and approximately 10,000 Fishman units of β-glucuronidase was added and incubated at 153 
37 °C overnight. Another aliquot of 10 mL urine was processed simultaneously without 154 
enzyme hydrolysis. Similarly an amount of 10 grams of faeces was weighed and mixed 155 
thoroughly with 10 mL of distilled water. The slurry is then centrifuged at 4000 ɡ for 15 156 
minutes. A volume of 7 mL of this clear liquid was adjusted to pH 5.2 and enzyme 157 
hydrolysed overnight at 37 °C. 158 
The enzyme hydrolysed urine and faeces samples were adjusted to pH 6.0 and again 159 
centrifuged for 15 minutes. To 5 mL of each sample 200 µL (1µg/mL) of internal standard 160 
was added and subjected to solid phase extraction as described above. The final eluent was 161 
dried and reconstituted with 50 µL of the mobile phase for LC/MS analysis. 162 
 163 
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In vitro metabolism of celecoxib 164 
To characterize the in vitro metabolic pathway, celecoxib was incubated with horse 165 
liver microsomes. In this study, all the incubations were performed in duplicates in a shaking 166 
water bath at 37°C. The experimental protocol is as follows: To 5 µL of celecoxib (1mM) is 167 
added 432 µL of 0.1M sodium phosphate buffer (pH 7.4) and 13 µL of the protein (0.5 168 
mg/mL), premixed and allowed to stand at room temperature for 3 minutes. The incubation 169 
was commended by the addition of 10 mM NADPH (50 µL) and allowed to react for 30 170 
minutes with constant gentle shaking. After incubation the reaction was quenched by addition 171 
of 100 µL of ice cold methanol. The resulting mixture was then extracted with 172 
dichloromethane, centrifuged and the organic phase was dried and reconstituted with 50 µL of 173 
the mobile phase for LC/MS analysis. 174 
 175 
Results  176 
The pharmacokinetic parameters of celecoxib after an oral dose of 2 mg/kg bwt are 177 
shown in Table 1. The results show that after oral administration of celecoxib the time to 178 
reach peak plasma concentration (tmax) was 4.58 ± 1.62 hours and the rate of elimination was 179 
calculated to be 0.05 ± 0.01 hr-1, while the terminal half-life (t1/2) was estimated to be 13.60 180 
± 3.18 hours. The mean ± standard deviation plasma concentration-time profile of celecoxib 181 
following oral single dose administration to six horses is graphically presented in Figure 1. 182 
Celecoxib was extensively metabolized after oral administration with low levels of the parent 183 
drug detected in urine for up to 72 hours. The majority of urinary metabolite consisted of 184 
carboxylic acid metabolite which was about 105.53 ng/mL and approximately 3 ng/mL of 185 
hydroxymethyl metabolite of celecoxib at 24 hours after oral administration. Moreover, this 186 
study shows that the carboxylic acid and hydroxymethyl metabolites of celecoxib could be 187 
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detected in urine for 96 and 48 hours respectively. However, the parent drug and carboxylic 188 
acid metabolite could be detected in faeces for 120 hours after administration (Figure 2). 189 
Further, the in vitro study using horse liver microsomes evidenced the formation of 190 
only two metabolites for the parent drug and no other transformations could be detected using 191 
a precursor ion/product ion scan by mass spectrometry (Figure 3). 192 
 193 
Discussion 194 
The use of a sensitive and specific analytical technique for the determination of 195 
celecoxib in biological samples is of paramount importance in pharmacokinetics study. High 196 
performance liquid chromatography with UV or fluorescence detection has been most widely 197 
used in the detection of celecoxib (Rose et al., 2000; Störmer et al., 2003; Zarghi et al., 2006). 198 
A liquid chromatography-tandem mass spectrometric quantitation of celecoxib in human 199 
plasma and rat, employing solid phase extraction was developed by (Bräutigam et al., 2001). 200 
Presently mass spectrometry has been predominantly used in the pharmacokinetics and 201 
metabolic study of celecoxib (Zhang et al., 2000; Werner et al., 2002; Ma et al., 2015). 202 
 The present pharmacokinetic data obtained from horses in this study when compared 203 
to humans and other animals is more or less in complete agreement for celecoxib oral 204 
administration, irrespective of the species differences (Paulson et al., 2000a ; Paulson et al., 205 
2001; Werner et al., 2002; Itthipanichpong et al., 2005; Park et al., 2012). However, in this 206 
study the plotted plasma concentration-time profile shows that there was a rapid increase in 207 
celecoxib level in about four hours and then the level decreases gradually reaching detectable 208 
levels up to approximately 96 hours following administration (Figure 1). Moreover, the large 209 
volume of distribution (Vd/F) and the slow elimination recorded in this study are suggesting 210 
extensive distribution of the drug and / or a poor bioavailability in the body of horses. 211 
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In the present study, the dosing of 2 mg/kg bwt was based on applying of more or less 212 
the same dose as reported for celecoxib urinary metabolism in horse (Dirikolu et al., 2001; De 213 
Kock et al., 2005), along with the assumption of equal efficacious plasma concentration 214 
between human and horse due to lack of experimental data; and unavailability of celecoxib 215 
pharmaceutical preparation in the veterinary market for horses. However, the found plasma 216 
clearance in this study (CL/F = 98.48 mL/kg/h) can be of a starting guide to extrapolate a 217 
provisional dose from another species assuming that the same overall body exposure (AUC) 218 
will produce the same effect in both species (Toutain & Bousquet-Mélou, 2004). Considering 219 
the extent of plasma binding is the same between humans and horses with equal 220 
bioavailability factor, F, celecoxib oral dose in horses can be extrapolated tentatively by 221 
applying equation (1); where the reported human plasma clearance (CL/F) for 3 mg/kg oral 222 
administration of celecoxib is 396 mL/kg/h (Brunton et al., 2018), the calculated dose for 223 
horses is about 0.75 mg/kg. Consequently, the average plasma concentration that would be 224 
achieved in steady-state condition in horses with chronic dosing of 0.75 mg/kg per day is 225 
about 317 ng/mL. 226 
Experimental results of this study advise a detection time in horse plasma of 227 
approximately 5 days when celecoxib is administered at 2mg/kg bwt based on the achieved 228 
analytical LOQ of 1ng/mL. This also was proven by the generic 229 
pharmacokinetic/pharmacodynamics approach (Toutain & Lassourd, 2002) based on the 230 
determinations of EPC, IPC, SF and the found PK parameters allowing computing of the 231 
detection time (DT) by the equations 2, 3 and 4; where the standard dose in this study is 232 
2mg/kg and the found plasma clearance is 98.48mL/kg/h, the calculated EPC is 846.20ng/mL. 233 
Applying a default safety factor of 500 (Toutain & Lassourd, 2002) will result in irrelevant 234 
plasma concentration of 1.70ng/mL. Where the slope of the terminal phase (β) found in the 235 
present study is 0.05 h-1 and drug maximum concentration in plasma is 1088 ng/mL, the 236 
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computed DT is 5.4 days more or less. Given the above, attention should be given for the 237 
change of detection time with a change in celecoxib dose, typically when applying the 238 
extrapolated therapeutic dose computed with Eqn (1). 239 
In humans, celecoxib has been found to be extensively metabolized in the liver with < 240 
3% is excreted unchanged and the major route of elimination are faeces and urine (Davies et 241 
al., 2000). A reported in vitro study for celecoxib metabolism using allelic variant forms of 242 
human liver microsomal cytochrome P450 2C9 evidenced the formation of three metabolites, 243 
namely: hydroxylated celecoxib, carboxycelecoxib and its corresponding glucuronide (Tang 244 
et al., 2001). In addition, it was reported that hydroxylation is the primary pathway of 245 
elimination in humans and is similar in several species such as mouse, rat, rabbit, dog and 246 
monkey while the carboxylic acid metabolite of celecoxib undergoes further glucuronidation 247 
to form carboxylic acid glucuronide and is excreted in urine (Paulson et al., 2000b; Paulson et 248 
al., 2001). However, an interesting observation is noticed on the elimination of celecoxib in 249 
horses that the parent drug is excreted as the major component compared to a significantly 250 
lower level of the carboxylic acid metabolite excreted in faeces (Figure 2). The high 251 
concentration of celecoxib in the faeces could be the unabsorbed drug. The two major urinary 252 
metabolites of celecoxib in horses were characterized and identified as 4-hydroxycelecoxib 253 
and 4-carboxycelecoxib (Dirikolu et al., 2001; De Kock et al., 2005). Moreover, it has been 254 
found that there was no appreciable change in the concentration of the carboxylic acid 255 
metabolite when using either hydrolysed or unhydrolysed urine suggesting that the drug or its 256 
metabolite is excreted without conjugation which is evidenced by the absence of any 257 
glucuronic acid conjugate when using a neutral loss screen by LC/MS. Hence, the carboxylic 258 
acid metabolite accounts for more than 90% and the parent drug accounts for 1-2% of the 259 
elimination of celecoxib in horse urine. 260 
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Rules for controlling medication of animals in competitions are established based on 261 
the possibility to increase artificially both the physical capability and the presence of a 262 
competitive instinct, using drugs. However, an anti-doping policy must not impede the use of 263 
legitimate therapeutic medications and most regulatory bodies in the world now distinguish 264 
the control of illicit substances (doping control) from the control of therapeutic substances 265 
(medication control) (Toutain, 2010). This study indicates that the detection of celecoxib and 266 
its carboxy metabolite are key elements for celecoxib doping investigation in horses, due to 267 
prolonged elimination profile and considerably high detection concentration in urine and 268 
faeces. It is concluded that a detection time of at least 5 days is advised for racing practitioner 269 
and veterinarians after administration of oral therapeutic dose of celecoxib at 2 mg/kg (body 270 
weight) to control its illegitimate use for horse racing. Attention should be given for 271 
computing the detection time upon administration of different oral dose. 272 
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Table 1 389 
Pharmacokinetic parameters of celecoxib in horses (n = 6) after a single oral solution 390 
administration at a dose of 2 mg/kg (body weight). Values are presented as means ± standard 391 
deviation (SD). 392 
Pharmacokinetic parameter Mean ± SD 
Drug maximum concentration in plasma (Cmax) ng/mL 1088 ± 324 
Time to reach peak plasma concentration (tmax) h 4.58 ± 1.62 
Rate of elimination (β) h-1 0.05 ± 0.01 
elimination half-life (t1/2β) h 13.60 ± 3.18 
Volume of distribution (Vd/F) mL/kg 1904.13 ± 974.69 
Clearance (CL/F) mL/h/kg 98.48 ± 48.16 
AUC0-t ng.h/mL 24142 ± 1096 
393 
 19 
Figure legends 394 
 395 
Figure 1: Time course changes (mean ± SD) of plasma concentration of celecoxib following 396 
oral administration of a single dose of 2 mg/kg body weight to 6 healthy horses. 397 
 398 
Figure 2: Time course changes of faecal excretion of celecoxib and its metabolite COOH-399 
celecoxib.  400 
 401 
Figure 3: LC-MS/MS extracted ion chromatogram and mass spectra of (A) celecoxib (RT = 6.65 402 
min), (B) hydroxymethyl celecoxib metabolite (RT = 6.10 min) and (C) celecoxib carboxylic acid 403 
metabolite (RT = 6.07) obtained from in vitro metabolism of celecoxib using horse liver mircorsomes. 404 
 405 
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